Praxis Precision Medicines, Inc. (NASDAQ: PRAX) continued its impressive rally in Friday's pre-market session, soaring 9.97% following a spectacular 183% gain on Thursday. The surge comes on the heels of the company's announcement of positive results from two pivotal Phase 3 trials for its essential tremor drug, ulixacaltamide, and the successful pricing of a $525 million public offering.

The clinical-stage biopharmaceutical company reported that both studies met their primary endpoints, demonstrating statistically significant and clinically meaningful improvements in patients' daily functioning and tremor control. This success positions Praxis as a frontrunner in movement disorder drug development, addressing a significant unmet need in the treatment of essential tremor, a condition that has not seen new approved treatments in over 50 years.

Adding to the positive momentum, Praxis announced the pricing of a $525 million public offering of shares and pre-funded warrants. The company is offering 3,025,480 shares at $157.00 per share, along with pre-funded warrants to purchase up to 318,470 shares. This substantial capital raise is expected to fund the company's efforts to bring ulixacaltamide to market, pending FDA approval.

The market's enthusiasm is further bolstered by analyst upgrades, with several firms significantly raising their price targets. TD Cowen increased its target from $61 to $251, while Deutsche Bank raised its target to $280 from $65. Analysts view ulixacaltamide as having blockbuster potential, with Jones Trading projecting U.S. risk-unadjusted peak sales of $12.2 billion by 2032. The unexpected success of the trials has taken many by surprise, as most investors had previously discounted the drug's potential following earlier setbacks.